Search the Newsreel

ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds

ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA)

Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) alleging investor harm due to false and misleading statements made by the company. The lawsuit claims ADMA engaged in an undisclosed related-party transaction, used channel stuffing, and …

Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA

Royal Bank of Canada significantly increased its stake in ADMA Biologics Inc. by 448.8% in the first quarter, purchasing 759,984 additional shares, bringing its total to 929,326 shares valued at approximately $8.37 million. ADMA Biologics recently reported quarterly EPS of $0.16, meeting expectations, though …

Janus Henderson Group PLC Trims Stock Holdings in ADMA Biologics Inc $ADMA

Janus Henderson Group PLC significantly reduced its stake in ADMA Biologics Inc by 97.5% in the first quarter, selling over 3.8 million shares and retaining 98,261 shares. Despite this, institutional investors still hold 75.68% of ADMA. The company reported in-line EPS but slightly missed …

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP ("SBS") has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged securities fraud, reminding investors who purchased shares during the class period (August 9, 2024, to March 25, 2026) to contact the firm regarding lead …

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP has reminded investors of the August 10, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit against ADMA Biologics, Inc. The lawsuit alleges that ADMA Biologics made false and misleading statements, including engaging in an undisclosed …

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) alleging misrepresentations regarding the company's financial condition, revenue recognition, inventory distribution, and business practices. The lawsuit claims that the company engaged in undisclosed related-party transactions and "channel stuffing," …

DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026

Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors. The lawsuit alleges misrepresentations regarding the company's financial condition, revenue recognition, inventory distribution, and business practices, including an undisclosed related party transaction and channel …

ADMA DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the …

Is ADMA Biologics (ADMA) Cheap On Lawsuit Risks Or Is Its Rebound Priced In?

ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

Kahn Swick & Foti, LLC (KSF) is reminding investors of ADMA Biologics, Inc. (ADMA) with losses over $100,000 that the deadline to file lead plaintiff applications in a securities class action lawsuit is August 10, 2026. The lawsuit alleges that ADMA and its executives …

ADMA BIOLOGICS CLASS ACTION DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. Stockholders to Contact the Firm Regarding Their Rights Before August 10th

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA made false statements and failed to disclose that it …

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged federal securities law violations between August 9, 2024, and March 25, 2026. Investors are accused of suffering losses due to undisclosed related-party transactions, …

ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA Biologics, Inc. Securities Class Action - Contact The Gross Law Firm

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead …

ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) alleging misrepresentations regarding the company's financial condition, revenue recognition, inventory distribution, and business practices. The lawsuit claims that the company engaged in an undisclosed related-party transaction and used …

ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

ADMA Biologics (ADMA) reported Q2 2026 earnings that matched analyst estimates at 16 cents per share, but revenues of $124.4 million missed expectations due to a significant decline in Bivigam sales. The company's Asceniv product, however, showed strong growth, helping to drive an expansion …

Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ADMA …

ADMA Biologics (Nasdaq: ADMA) grows Q2 profit and ASCENIV sales

ADMA Biologics reported significantly higher profitability in Q2 2026, driven by strong ASCENIV sales, despite modest overall revenue growth. The company announced a 24% increase in ASCENIV revenue, contributing to a 69% gross margin and an 11% rise in GAAP net income. ADMA reiterated …

ADMA Biologics (ADMA) Is Up 6.3% After Faster Net Income Growth Than Sales In Q2 2026

ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...

Earnings call transcript: ADMA Biologics posts strong margins in Q2 2026

This article first appeared on GuruFocus. Total Revenue: $124.4 million in Q2 2026, a 2% increase year-over-year. Ascentiv Revenue: $102.9 million, up 24% year-over-year. Bivigam Revenue: $19.4 million, reflecting sequential improvement from Q1. Gross Margin: 69%, up from 55% in the prior-year period. Adjusted …

ADMA reiterates 2026 guidance of $530M-$560M revenue while targeting $200M+ in share repurchases

Earnings Call Insights: ADMA Biologics (ADMA) Q2 2026 MANAGEMENT VIEW * Adam Grossman (Co-Founder, President, CEO & Director) framed Q2 as accelerating demand for the company’s higher-margin immunoglobulin product: “ASCENIV demand accelerated during the second quarter, and June delivered the strongest sequential utilization growth …

Earnings Flash (ADMA) ADMA Biologics, Inc. Reports Q2 Revenue $124.4M, vs. FactSet Est of $125.3M

ADMA Biologics, Inc. reported its Q2 revenue at $124.4 million, which was slightly below the FactSet estimate of $125.3 million. The company, a biopharmaceutical firm specializing in plasma-derived biologics, is scheduled to hold its Q2 2026 Earnings Call on August 5, 2026. This earnings …

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMA Biologics reported strong second-quarter 2026 financial results, with total revenue reaching $124.4 million, up 2% year-over-year, driven primarily by ASCENIV sales which grew 24% to $102.9 million. The company reiterated its full-year 2026 financial guidance and highlighted new real-world data supporting ASCENIV's effectiveness …

DEADLINE NEXT WEEK: Berger Montague Advises ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Contact the Firm Before August 10, 2026

PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”) on behalf of investors who purchased or acquired ADMA common stock during the period from …

ADMA Biologics earnings up next: Can plasma maker rebound? By Investing.com

ADMA Biologics is set to report second-quarter earnings, with investors focused on whether the company can rebound from a disappointing prior quarter. Despite recent declines in analyst estimates, Wall Street remains optimistic with a mean price target of $17, implying significant upside. Key factors …

ADMA Biologics Inc earnings missed, revenue fell short of estimates

ADMA Biologics (ADMA) Earnings Date and Reports 2026

ADMA BIOLOGICS, INC. Quarterly Earnings Report

ADMA Biologics (NASDAQ:ADMA) Posts Earnings Results, Hits Expectations

ASCENIV Q2 Revenue Rises 24% to $102.9M at ADMA Biologics

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMA

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, …